Endologix®Inc., a developer and marketer of innovative treatments for aortic disorders, announced that it has received approval from the United States Food and Drug Administration (FDA) for the Alto™Abdominal Stent Graft System(Alto).
The Company received approval based on its regulatory submission that includes the ELEVATE Investigational Device Exemption (IDE)clinical study. Pursuant to the terms of approval, the first 100 patients after commercial launch will be included in a post approval imaging study to determine consistency in device selection between Endologix’sinternal imaging services and those of the implanting physicians.
“We are thrilled to receive approval for the Alto system,”commented Matt Thompson, Chief Medical Officer of Endologix. “We have worked collaboratively with the FDA throughout the Alto premarket approval (PMA) process, and we will be carefully monitoring intra-procedural events as Alto ramps to full commercialization. We anticipate observing improved short-term outcomes relative to the Ovation iX Abdominal Stent Graft System (Ovation iX) as a result of the design and manufacturing changes incorporated intoAlto. However,as we expect Ovation iX to remain commercially available for a period of time subsequent to theAlto launch, we will also be updating our previous2018 safety communication as it relates to the Ovation iX system.”
“Alto approval is acritical landmark for Endologix as we seek to introduce a portfolio of devices to address the current unmet needs of endovascular aneurysm repair (EVAR),” commented John Onopchenko, Chief Executive Officer of Endologix. “Alto is a differentiated EVAR device that offers significant design features that we believe will enhance ease of use,improve acute outcomes,and preserve the long-term durability associated with patient-specific anatomically adaptive sealing. We
believe Alto’sultra-low profile and its7mm aortic neck length indication give it the broadest applicability of any endograft in the U.S.We are committed to proving the superiority of this product over traditional undifferentiated EVAR grafts in a randomized clinical trial, while remaining steadfastly focused on re-establishing durable, predictable growth through a continued focus on execution and evidence-driven differentiation.”
About Endologix, Inc.
Endologixdevelops and manufactures minimally invasive treatments for aortic disorders. The Company’s focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms . AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once an AAAdevelops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 80%, making it a leading cause of death in theU.S.
